Rousselot Announces Partnership with Terasaki Institute for Biomedical Innovation

Irving, United States, 12th January 2022 / Sciad Newswire / Rousselot^®, Darling Ingredients’ health brand and the world’s leader of collagen-based solutions, today announced that it has partnered with the Terasaki Institute for Biomedical Innovation (TIBI), a California-based research institute focused on regenerative medicine. Through this strategic partnership, Rousselot and TIBI will collaborate on the development of gelatin-based therapies and their translation to the clinic. Rousselot will supply TIBI with X-Pure^® modified gelatins such as X-Pure GelMA, while exchanging insights on the behavior of gelatin in the institute's research and clinical trials.

With more than 130 years of gelatin and collagen expertise, Rousselot created X-Pure, a full range of biomedical gelatins and modified gelatins, characterized by their unmatched purity (<10EU/g endotoxin) and consistency, as well as full compliance with GMP. Part of this range, Rousselot’s X-Pure GelMA modified gelatins have already been tested and recognized for their premium quality by TIBI’s researchers.

“We are excited to partner with Rousselot and to be able to use Rousselot’s modified gelatins for our research,” explains Ali Khademhosseini, CEO of TIBI. “Modified gelatins have proven to be powerful biomaterials in the regenerative medicine field, and we have been using them heavily over the past few years. I am certain that high-quality, purified GelMA will support both our in vitro and in vivo research and development. With X-Pure GelMA, we will be able to make further strides in the clinical translation of our research to accelerate the development of new therapies.”

“We are delighted to work together with TIBI and its team of world-renowned researchers,” said Jos Vervoort, Rousselot’s Executive Vice-President. “X-Pure modified gelatins are low-endotoxin, batch-to-batch consistent and GMP ready, making them suitable for research and clinical translation. Their purity and scalability will support the full cycle of research and clinical development and we are proud to play a role in helping the experts at TIBI translate their research into viable biomedical solutions that can help patients across the planet.”

The Partnership is effective from January 1^st, 2022, and will have an initial duration of two years, fostering a close collaboration between TIBI’s experts on microneedles and 3D-bioprinting and Rousselot’s experts in collagen- and gelatin-based biomaterials.  

ENDS

Notes to Editors

For more information, contact:

Rousselot
Caroline Brochard-Garnier
[e] caroline.brochard-garnier@rousselot.com 

Sciad Communications
Maria Patey / Sophie Protheroe
[e] rousselot@sciad.com  

About the Terasaki Institute for Biomedical Innovation
The TIBI is a non-profit research organization that invents and fosters practical solutions that restore or enhance the health of individuals. The Institute is made possible through an endowment from the late Dr. Paul I. Terasaki, a pioneer in the field of organ transplant technology. www.terasaki.org

About Rousselot^® Biomedical
As the most recent strategic segment within Rousselot, we have drawn upon Rousselot’s 130+ years of worldwide expertise and proven track record of pharmaceutical gelatins and collagens to develop innovative ranges of purified, modified and non-modified gelatins and collagens for biomedical applications. Offering unique advantages to assure performance, quality and safety from bench to clinic, Rousselot^® X-Pure^® and Rousselot^® Quali-Pure™ provide consistent quality and are backed by strong scientific data and ongoing research. Rousselot Biomedical is committed to supporting end-to-end partnerships to help “advancing medical science”. www.rousselot.com/biomedical